The next generation of phosphodiesterase inhibitors: Structural clues to ligand and substrate selectivity of phosphodiesterases

Journal of Medicinal Chemistry

Volumn 48, Issue 10, 2005, Pages 3449-3462

  Manallack, David T ^a   Hughes, Richard A ^b   Thompson, Philip E ^a  

^a MONASH UNIVERSITY   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

9 (2 HYDROXY 3 NONYL)ADENINE; ADENOSINE PHOSPHATE; BAY 607550; CILOMILAST; CILOSTAMIDE; CYCLIC AMP; CYCLIC GMP; DIPYRIDAMOLE; GUANOSINE PHOSPHATE; ISOBUTYLMETHYLXANTHINE; MILRINONE; PAPAVERINE; PHOSPHODIESTERASE; PHOSPHODIESTERASE INHIBITOR; ROFLUMILAST; ROLIPRAM; SILDENAFIL; SULINDAC SULFONE; TADALAFIL; THEOPHYLLINE; UK 343664; UNCLASSIFIED DRUG; VARDENAFIL; VINPOCETINE; ZAPRINAST; ZARDAVERINE;

DRUG BINDING SITE; DRUG STRUCTURE; ENZYME ACTIVE SITE; ENZYME SPECIFICITY; REVIEW; SEQUENCE ALIGNMENT; SEQUENCE HOMOLOGY; STRUCTURE ACTIVITY RELATION;

ANIMALS; BINDING SITES; CRYSTALLOGRAPHY, X-RAY; CYCLIC AMP; CYCLIC GMP; DRUG DESIGN; HUMANS; MODELS, MOLECULAR; MOLECULAR STRUCTURE; PHOSPHODIESTERASE INHIBITORS; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP; XANTHINES;

EID: 18644376713     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm040217u     Document Type: Review

References (66)

1. Soderling, S. H.; Beavo, J. A. Regulation of cAMP and cGMP signaling: new phosphodiesterases and new functions. Curr. Opin. Cell Biol. 2000, 12, 174-179.
2. Conti, M.; Jin, S.-L. C. The molecular biology of cyclic nucleotide phosphodiesterases. Prog. Nucleic Acid Res. Mol. Biol. 2000, 63, 1-38.
3. Mehats, C.; Andersen, C. B.; Filopanti, M.; Jin, S.-L. C.; Conti, M. Cyclic nucleotide phosphodiesterases and their role in endocrine cell signaling. Trends. Endocrinol. Metab. 2002, 13, 29-35.
4. Sutherland, E. W.; Rall, T. W. Fractionation and characterization of a cyclic adenine ribonucleotide formed by tissue particles. J. Biol. Chem. 1958, 232, 1077-1091.
5. Weishaar, R. E.; Cain, M. H.; Bristol, J. A. A new generation of phosphodiesterase inhibitors: multiple molecular forms of phosphodiesterase and the potential for drug selectivity. J. Med. Chem. 1985, 28, 537-545.
6. Manganiello, V. C.; Degerman, E. Cyclic nucleotide phosphodiesterases (PDEs): diverse regulators of cyclic nucleotide signals and inviting molecular targets for novel therapeutic agents. Thromb. Haemostasis 1999, 82, 407-411.
7. Houslay, M. D.; Adams, D. R. PDE4 cAMP phosphodiesterases: modular enzymes that orchestrate signalling cross-talk, desensitization and compartmentalization. Biochem. J. 2003, 370, 1-18.
8. Muller, T.; Engels, P.; Fozard, J. R. Subtypes of the type 4 cAMP phosphodiesterases: structure, regulation and selective inhibition. Trends Pharmacol. Sci. 1996, 17, 294-298.
9. Torphy, T. Phosphodiesterase isozymes: molecular targets for novel antiasthma agents. Am. J. Respir. Crit. Care Med. 1998, 157, 351-370.
10. Corbin, J., D.; Francis, S. H. Cyclic GMP phosphodiesterase-5: target of sildenafil. J. Biol. Chem. 1999, 274, 13729-13732.
11. Francis, S. H. T. I.; Corbin, J. D. Cyclic nucleotide phosphodiesterases: relating structure and function. Prog. Nucleic Acid Res. Mol. Biol. 2001, 65, 1-52.
12. Conti, M.; Richter, W.; Mehats, C.; Livera, G.; Park, J. Y.; et al. Cyclic AMP-specific PDE4 phosphodiesterases as critical components of cyclic AMP signaling. J. Biol. Chem. 2003, 278, 5493-5496.
13. Xu, R. X.; Hassell, A. M.; Vanderwall, D.; Lambert, M. H.; Holmes, W. D.; et al. Atomic structure of PDE4: insights into phosphodiesterase mechanism and specificity. Science 2000, 288, 1822-1825.
14. Scapin, G.; Patel, S. B.; Chung, C.; Varnerin, J. P.; Edmondson, S. D.; et al. Crystal structure of human phosphodiesterase 3B: atomic basis for substrate and inhibitor specificity. Biochemistry 2004, 43, 6091-6100.
15. Xu, R. X.; Rocque, W. J.; Lambert, M. H.; Vanderwall, D. E.; Luther, M. A.; et al. Crystal structures of the catalytic domain of phosphodiesterase 4B complexed with AMP, 8-Br-AMP, and rolipram. J. Mol. Biol. 2004, 337, 355-365.
16. Huai, Q.; Liu, Y.; Francis, S. H.; Corbin, J. D.; Ke, H. Crystal structures of phosphodiesterases 4 and 5 in complex with inhibitor 3-isobutyl-1-methylxanthine suggest a conformation determinant of inhibitor selectivity. J. Biol. Chem. 2004, 279, 13095-13101.
17. Huai, Q.; Wang, H.; Zhang, W.; Colman, R. W.; Robinson, H.; et al. Crystal structure of phosphodiesterase 9 shows orientation variation of inhibitor 3-isobutyl-1-methylxanthine binding. Proc. Natl. Acad. Sci. U.S.A. 2004, 101, 9624-9629.
18. Zhang, K. Y.; Card, G. L.; Suzuki, Y.; Artis, D. R.; Fong, D.; et al. A glutamine switch mechanism for nucleotide selectivity by phosphodiesterases. Mol. Cell 2004, 15, 279-286.
19. Huai, Q.; Wang, H.; Sun, Y.; Kim, H. Y.; Liu, Y.; et al. Three-dimensional structures of PDE4D in complex with roliprams and implication on inhibitor selectivity. Structure 2003, 11, 865-873.
20. Sung, B. J.; Yeon, H. K.; Ho, J. Y.; Lee, J. I.; Heo, Y. S.; et al. Structure of the catalytic domain of human phosphodiesterase 5 with bound drug molecules. Nature 2003, 425, 98-102.
21. Huai, Q.; Colicelli, J.; Ke, H. The crystal structure of AMP-bound PDE4 suggests a mechanism for phosphodiesterase catalysis. Biochemistry 2003, 42, 13220-13226.
22. Lohse, D. L.; Denu, J. M.; Dixon, J. E. Insights derived from the structures of the Ser/Thr phosphatases calcineurin and protein phosphatase 1. Structure 1995, 3, 987-990.
23. Huai, Q.; Kim, H. Y.; Liu, Y.; Zhao, Y.; Mondragon, A.; et al. Crystal structure of calcineurin-cyclophilin-cyclosporin shows common but distinct recognition of immunophilin-drug complexes. Proc. Natl. Acad. Sci. U.S.A. 2002, 99, 12037-12042.
24. Thompson, J. D.; Higgins, D. G.; Gibson, T. J. CLUSTAL W: Improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice. Nucleic Acids Res. 1994, 22, 4673-4680.
25. Zhang, W.; Ke, H.; Colman, R. W. Identification of interaction sites of cyclic nucleotide phosphodiesterase type 3A with milrinone and cilostazol using molecular modeling and site-directed mutagenesis. Mol. Pharmacol. 2002, 62, 514-520.
26. Zhang, W.; Ke, H.; Tretiakova, A. P.; Jameson, B.; Colman, R. W. Identification of overlapping but distinct cAMP and cGMP interaction sites with cyclic nucleotide phosphodiesterase 3A by site-directed mutagenesis and molecular modeling based on crystalline PDE4B. Protein Sci. 2001, 10, 1481-1489.
27. Fossa, P.; Giordanetto, F.; Menozzi, G.; Mosti, L. Structural basis for selective PDE3 inhibition: a docking study. Quant. Struct. - Act. Relat. 2002, 21, 267-275.
28. Salter, E. A.; Wierzbicki, A.; Sperl, G.; Thompson, W. J. Homology models of the catalytic sites of phosphodiesterase 5A and 10A and molecular docking of selective apoptotic antineoplastic drugs (SAANDs). Int. J. Quantum Chem. 2004, 96, 402-410.
29. Dym, O.; Xenarios, I.; Ke, H.; Colicelli, J. Molecular docking of competitive phosphodiesterase inhibitors. Mol. Pharmacol. 2002, 61, 20-25.
30. Chung, C.; Varnerin, J. P.; Morin, N. R.; MacNeil, D. J.; Singh, S. B.; et al. The role of tryptophan 1072 in human PDE3B inhibitor binding. Biochem. Biophys. Res. Commun. 2003, 307, 1045-1050.
31. Tang, K. M.; Jang, E. K.; Haslam, R. J. Expression and mutagenesis of the catalytic domain of cGMP-inhibited phosphodiesterase (PDE3) cloned from human platelets. Biochem. J. 1997, 323 (Part 1), 217-224.
32. Manganiello, V. C.; Taira, M.; Degerman, E.; Belfrage, P. Type III cGMP-inhibited cyclic nucleotide phosphodiesterases (PDE3 gene family). Cell. Signalling 1995, 7, 445-455.
33. Terrett, N. K.; Bell, A. S.; Brown, D.; Ellis, P. Sildenafil (viagra(TM)), a potent and selective inhibitor of type 5 cGMP phosphodiesterase with utility for the treatment of male erectile dysfunction. Bioorg. Med. Chem. Lett. 1996, 6, 1819-1824.
34. Arnold, R.; Beer, D.; Bhalay, G.; Baettig, U.; Collingwood, S. P.; et al. 8-Aryl xanthines potent inhibitors of phosphodiesterase 5. Bioorg. Med. Chem. Lett. 2002, 12, 2587-2590.
35. Maurice, D. H.; Palmer, D.; Tilley, D. G.; Dunkerley, H. A.; Netherton, S. J.; et al. Cyclic nucleotide phosphodiesterase activity, expression, and targeting in cells of the cardiovascular system. Mol. Pharmacol. 2003, 64, 533-546.
36. Fujishige, K.; Kotera, J.; Michibata, H.; Yuasa, K.; Takebayashi, S.; et al. Cloning and characterization of a novel human phosphodiesterase that hydrolyzes both cAMP and cGMP (PDE10A). J. Biol. Chem. 1999, 274, 18438-18445.
37. 2+-calmodulin sensitive phosphodiesterase (PDE I). Bioorg. Med. Chem. Lett. 1997, 7, 89-94.
38. Stamford, A. W. Phosphodiesterase 5 inhibitors. Annu. Rep. Med. Chem. 2002, 37, 53-64.
39. Cote, R. H. Characteristics of photoreceptor PDE (PDE6): similarities and differences to PDE5. Int. J. Impot. Res. 2004, 16 (Suppl. 1), S28-S33.
40. Corbin, J. D.; Francis, S. H. Pharmacology of phosphodiesterase-5 inhibitors. Int. J. Clin. Pract. 2002, 56, 453-459.
41. Abel, S.; Beaumont, K. C.; Crespi, C. L.; Eve, M. D.; Fox, L.; et al. Potential role for P-glycoprotein in the non-proportional pharmacokinetics of UK-343,664 in man. Xenobiotica 2001, 31, 665-676.
42. Marivet, M. C.; Bourguignon, J. J.; Lugnier, C.; Mann, A.; Stoclet, J. C.; et al. Inhibition of cyclic adenosine-3′,5′-monophosphate phosphodiesterase from vascular smooth muscle by rolipram analogues. J. Med. Chem. 1989, 32, 1450-1457.
43. Lee, M. E.; Markowitz, J.; Lee, J. O.; Lee, H. Crystal structure of phosphodiesterase 4D and inhibitor complex. FEBS Lett. 2002, 530, 53-58.
44. Barnette, M. S.; Christensen, S. B.; Essayan, D. M.; Grous, M.; Prabhakar, U.; et al. SB 207499 (Ariflo), a potent and selective second-generation phosphodiesterase 4 inhibitor: in vitro anti-inflammatory actions. J. Pharmacol. Exp. Ther. 1998, 284, 420-426.
45. Hatzelmann, A.; Schudt, C. Anti-inflammatory and immunomodulatory potential of the novel PDE4 inhibitor roflumilast in vitro. J. Pharmacol. Exp. Ther. 2001, 297, 267-279.
46. Montana, J. G.; Dyke, H. J. Phosphodiesterase 4 Inhibitors. Annu. Rep. Med. Chem. 2001, 41-56.
47. Keller, T. H.; Bray-French, K.; Demnitz, F. W.; Muller, T.; Pombo-Villar, E.; et al. Synthesis and structure-activity relationship of N-arylrolipram derivatives as inhibitors of PDE4 isozymes. Chem. Pharm. Bull. (Tokyo) 2001, 49, 1009-1017.
48. Robichaud, A.; Stamatiou, P. B.; Jin, S. L.; Lachance, N.; MacDonald, D.; et al. Deletion of phosphodiesterase 4D in mice shortens alpha(2)-adrenoceptor- mediated anesthesia, a behavioral correlate of emesis. J. Clin. Invest. 2002, 110, 1045-1052.
49. O'Donnell, J. M.; Zhang, H. T. Antidepressant effects of inhibitors of cAMP phosphodiesterase (PDE4). Trends Pharmacol. Sci. 2004, 25, 158-163.
50. Van der Mey, M.; Bommele, K. M.; Boss, H.; Hatzelmann, A.; Van Slingerland, M.; et al. Synthesis and structure-activity relationships of cis-tetrahydrophthalazinone/pyridazinone hybrids: a novel series of potent dual PDE3/PDE4 inhibitory agents. J. Med. Chem. 2003, 46, 2008-2016.
51. Hann, M. M.; Leach, A. R.; Harper, G. Molecular complexity and its impact on the probability of finding leads for drug discovery. J. Chem. Inf. Comput. Sci. 2001, 41, 856-864.
52. Oprea, T. I.; Davis, A. M.; Teague, S. J.; Leeson, P. D. Is there a difference between leads and drugs? A historical perspective. J. Chem. Inf. Comput. Sci. 2001, 41, 1308-1315.
53. Beavo, J. A.; Brunton, L. L. Cyclic nucleotide research - still expanding after half a century. Nat. Rev. Mol. Cell Biol. 2002, 3, 710-718.
54. Hirsh, L.; Dantes, A.; Suh, B. S.; Yoshida, Y.; Hosokawa, K.; et al. Phosphodiesterase inhibitors as anti-cancer drugs. Biochem. Pharmacol. 2004, 68, 981-988.
55. Perry, M. J.; Higgs, G. A. Chemotherapeutic potential of phosphodiesterase inhibitors. Curr. Opin. Chem. Biol. 1998, 2, 472-481.
56. Boess, F. G.; Hendrix, M.; van der Staay, F. J.; Erb, C.; Schreiber, R.; et al. Inhibition of phosphodiesterase 2 increases neuronal cGMP, synaptic plasticity and memory performance. Neuropharmacology 2004, 47, 1081-1092.
57. Vergne, F.; Bernardelli, P.; Lorthiois, E.; Pham, N.; Proust, E.; et al. Discovery of thiadiazoles as a novel structural class of potent and selective PDE7 inhibitors. Part 1: design, synthesis and structure-activity relationship studies. Bioorg. Med. Chem. Lett. 2004, 14, 4607-4613.
58. Lorthiois, E.; Bernardelli, P.; Vergne, F.; Oliveira, C.; Mafroud, A. K.; et al. Spiroquinazolinones as novel, potent, and selective PDE7 inhibitors. Part 1. Bioorg. Med. Chem. Lett. 2004, 14, 4623-4626.
59. Barnes, M. J.; Cooper, N.; Davenport, R. J.; Dyke, H. J.; Galleway, F. P.; et al. Synthesis and structure-activity relationships of guanine analogues as phosphodiesterase 7 (PDE7) inhibitors. Bioorg. Med. Chem. Lett. 2001, 11, 1081-1083.
60. Li, L.; Yee, C.; Beavo, J. A. CD3- and CD28-dependent induction of PDE7 required for T cell activation. Science 1999, 283, 848-851.
61. Yang, G.; McIntyre, K. W.; Townsend, R. M.; Shen, H. H.; Pitts, W. J.; et al. Phosphodiesterase 7A-deficient mice have functional T cells. J. Immunol. 2003, 171, 6414-6420.
62. Thompson, W. J.; Piazza, G. A.; Li, H.; Liu, L.; Fetter, J.; et al. Exisulind induction of apoptosis involves guanosine 3′,5′-cyclic monophosphate phosphodiesterase inhibition, protein kinase G activation, and attenuated beta-catenin. Cancer Res. 2000, 60, 3338-3342.
63. Blundell, T. L.; Patel, S. High-throughput X-ray crystallography for drug discovery. Curr. Opin. Pharmacol. 2004, 4, 490-496.
64. Tickle, I.; Sharff, A.; Vinkovic, M.; Yon, J.; Jhoti, H. High-throughput protein crystallography and drug discovery. Chem. Soc. Rev. 2004, 33, 558-565.
65. Card, G. L.; England, B. P.; Suzuki, Y.; Fong, D.; Powell, B.; et al. Structural basis for the activity of drugs that inhibit phosphodiesterases. Structure (Cambridge) 2004, 12, 2233-2247.
66. Card, G. L.; Blasdel, L.; England, B. P.; Zhang, C.; Suzuki, Y.; et al. A family of phosphodiesterase inhibitors discovered by cocrystallography and scaffold-based drug design. Nat. Biotechnol. 2005, 23, 201-207.